

# Niger

Population 2016

21 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	4 (2.4–6.1)	20 (12–30)
Mortality (HIV+TB only)	0.39 (0.24–0.57)	1.9 (1.2–2.7)
Incidence (includes HIV+TB)	19 (12–27)	93 (60–132)
Incidence (HIV+TB only)	0.95 (0.6–1.4)	4.6 (2.9–6.6)
Incidence (MDR/RR-TB)**	0.66 (0.14–1.2)	3.2 (0.67–5.7)

## Estimated TB incidence by age and sex (thousands)\*, 2016

	0-14 years	> 14 years	Total
Females	1 (0.63–1.4)	6.2 (3.8–8.7)	7.3 (4.4–10)
Males	1.2 (0.72–1.6)	11 (6.5–15)	12 (7.2–17)
Total	2.2 (1.3–3.1)	17 (10–24)	19 (12–27)

## TB case notifications, 2016

Total cases notified	10 165
Total new and relapse	9 921
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	74%
- % pulmonary	87%
- % bacteriologically confirmed among pulmonary	89%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	52% (36–80)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.24 (0.12–0.39)

## TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	378	5%
- on antiretroviral therapy	374	99%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			330 (92–570)
Estimated % of TB cases with MDR/RR-TB	2.6% (0.1–5.1)	18% (0.1–36)	
% notified tested for rifampicin resistance	<1%	43%	287
MDR/RR-TB cases tested for resistance to second-line drugs			34
Laboratory-confirmed cases		MDR/RR-TB: 49, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 46, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	80%	10 323
Previously treated cases, excluding relapse, registered in 2015	66%	243
HIV-positive TB cases registered in 2015	62%	428
MDR/RR-TB cases started on second-line treatment in 2014	78%	46
XDR-TB cases started on second-line treatment in 2014		0

## TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	12%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	20% (19–22)

## TB financing, 2017

National TB budget (US\$ millions)

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2016




## Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

## Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically